BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director V Bryan Lawlis Sells 3,750 Shares of Stock
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director V Bryan Lawlis sold 3,750 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $74.47, for a total value of $279,262.50. Following the completion of the sale, the director now owns 27,340 shares of the company’s stock, valued at $2,036,009.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
BMRN traded down $0.33 during midday trading on Thursday, reaching $75.17. 12,874 shares of the company were exchanged, compared to its average volume of 955,794. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.79 and a current ratio of 4.11. BioMarin Pharmaceutical Inc. has a one year low of $70.82 and a one year high of $106.74. The stock has a market capitalization of $13.53 billion, a P/E ratio of -226.89 and a beta of 1.32. The stock’s 50-day simple moving average is $75.31 and its 200 day simple moving average is $83.43.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.16). BioMarin Pharmaceutical had a negative return on equity of 3.12% and a negative net margin of 7.19%. The company had revenue of $388.00 million for the quarter, compared to the consensus estimate of $415.03 million. During the same quarter last year, the business posted ($0.09) EPS. BioMarin Pharmaceutical’s quarterly revenue was up 4.0% on a year-over-year basis. On average, research analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.03 earnings per share for the current year.
A number of brokerages recently commented on BMRN. Wedbush reiterated an “outperform” rating and issued a $128.00 price objective on shares of BioMarin Pharmaceutical in a research report on Wednesday, July 10th. Citigroup reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Thursday, May 23rd. BidaskClub upgraded BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday. Piper Jaffray Companies set a $120.00 price objective on BioMarin Pharmaceutical and gave the stock a “buy” rating in a research report on Friday, September 13th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and issued a $133.00 price objective on shares of BioMarin Pharmaceutical in a research report on Monday, August 5th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $115.33.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Story: Market Capitalization
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.